• Mashup Score: 1

    Objective Exhausted hepatitis B virus (HBV)-specific CD8 T cells in chronic HBV infection are broadly heterogeneous. Characterisation of their functional impairment may allow to distinguish patients with different capacity to control infection and reconstitute antiviral function. Design HBV dextramer+CD8 T cells were analysed ex vivo for coexpression of checkpoint/differentiation markers, transcription factors and cytokines in 35 patients with HLA-A2+chronic hepatitis B (CHB) and in 29 control HBsAg negative CHB patients who seroconverted after NUC treatment or spontaneously. Cytokine production was also evaluated in HBV peptide-stimulated T cell cultures, in the presence or absence of antioxidant, polyphenolic, PD-1/PD-L1 inhibitor and TLR-8 agonist compounds and the effect on HBV-specific responses was further validated on additional 24 HLA-A2 negative CHB patients. Results Severely exhausted HBV-specific CD8 T cell subsets with high expression of inhibitory receptors, such as PD-1,

    Tweet Tweets with this article
    • #GUTImage from the paper by Rossi and Vecchi et al entitled "Phenotypic CD8 T cell profiling in chronic hepatitis B to predict HBV-specific CD8 T cell susceptibility to functional restoration in vitro" via https://t.co/VDki1euSod #HBV #HepatitisB https://t.co/2XZyiblBOU

  • Mashup Score: 6

    In 2022, the Global Fund to Fight AIDS, Tuberculosis and Malaria made a welcome move to enable increased financial support for viral hepatitis. International organisations and patient groups have called on countries to include viral hepatitis prevention and treatment services in their national proposals to the Global Fund, and also called on funders such as the US President’s Emergency Plan for AIDS Relief (PEPFAR) to integrate viral hepatitis into their programmes.1

    Tweet Tweets with this article
    • New Correspondence - Khwairakpam et al - HIV pre-exposure prophylaxis as an entry point to the elimination of hepatitis B virus https://t.co/FQ0cQHskeF #TREATAsia @amfAR @Hep_Alliance @hepatitisfund #NoHep #HBV #HIV

  • Mashup Score: 3

    An estimated 20–30% of people with hepatitis B virus (HBV) infection will die in the absence of antiviral treatment.1 Until now, international liver society guidelines have been based on the same logic: to try to identify these higher risk patients so that treatment can be initiated before they develop irreversible complications.2–4 Typically, treatment decisions are based on clinical signs, liver fibrosis assessment by transient elastography, and blood tests such as serum aminotransferase and HBV DNA concentrations.

    Tweet Tweets with this article
    • "Is it time for a paradigm shift in treatment guidelines for chronic hepatitis B?" In our new issue, @dr_asgeir suggests a "treat all expect..." approach for people with #HBV infection, with diagnostics used to identify those not needing treatment https://t.co/HrYpLi6tkp https://t.co/RTvkImk8KY

  • Mashup Score: 0

    In The Lancet Gastroenterology & Hepatology, the Polaris Observatory Collaborators report their latest iteration of the modelling of HBV prevalence, cascade of care, and prophylaxis.1 Some refinements have been made to the modelling, with better quality data, which have led to an estimated global burden of HBV infection of 257·5 million (95% uncertainty interval 216·6–316·4) in 2022—a reduction of around 34·5 million cases compared with the 292·0 million estimated for 2016.2 By contrast, Cui and colleagues’ recent study,3 which used WHO-collected data, estimated that 295·9 million (95% CI 228·2–422·6) people were living with chronic HBV infection in 2019.

    Tweet Tweets with this article
    • Linked Comment by @SengGeeLim1 - WHO 2030 HBV elimination goals: a goal too far? https://t.co/3Cd9qbSBuU #NoHep #HBV #WorldHepatitisDay #LiverTwitter #IDTwitter https://t.co/0bjE173eFY

  • Mashup Score: 10

    In 2008, the World Hepatitis Alliance launched the World Hepatitis Day in honour of the birthday of Dr Baruch Blumberg (July 28, 1925), who discovered the hepatitis B virus (HBV) in 1967. The worldwide number of deaths per year attributable to HBV was estimated at 700 000 in 2013. This number is projected to increase to 1·3 million per year by 2040, which is more than the annual number of deaths related to HIV/AIDS (741 000), tuberculosis (875 000), or malaria (332 000).1

    Tweet Tweets with this article
    • New Correspondence - Vo-Quang et al - Poor disease knowledge among people living with hepatitis B in The Gambia and Tanzania https://t.co/cZuNZ9cIVw #LiverTwitter #IDTwitter #WorldHepatitisDay #NoHep #HepCantWait #NotWaiting #HBV @maud_lemoine @ErwanVoQuang @gndow https://t.co/ijK3JKArGY